Table 3. Representation of the Summarized Sequential Passage Data.
| MIC
(μM) |
|||||
|---|---|---|---|---|---|
| bacteria strain | antibacterial agent | number of passages | initial | final | fold change in MICa |
| E. coli | (AB-20)17 | 25 | 12 | 12 | no resistance |
| ciprofloxacin | 25 | 0.188 | 48.28 | 256 | |
| (AB-20)27 | 30 | 6.5 | 6.5 | no resistance | |
| ciprofloxacin | 30 | 0.09 | 24.1 | 256 | |
| S. aureus | (AB-20)17 | 25 | 14 | 14 | no resistance |
| ciprofloxacin | 25 | 0.75 | 48.28 | 64 | |
| (AB-20)27 | 30 | 6.5 | 6.5 | no resistance | |
| ciprofloxacin | 30 | 0.75 | 24.1 | 32 | |
a
A 4-fold increase in MIC from the original MIC value is considered resistance development.